Answer
Yes, tumour lysis syndrome has been reported in patients receiving isatuximab, so close monitoring and appropriate precautions are required.
Sources for this answer
- SARCLISA 20mg/mL concentrate for solution for infusionSANOFI · emc · SmPC §4.4 Special warnings and precautions for use · Version 10Document updated
Sources checked